A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

Phase 1 Completed 35 enrolled Pfizer

RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine PF-07261271 for the potential treatment of Inflammatory Bowel Disease.

Timeline

Start: 2022-10-17
Primary completion: 2024-02-29
Completion: 2024-02-29

Publications

Neelakantan S, Banfield C, Hung K, Sapone A, Pradhan V, Zhao Y, Parsons-Rich D, Lee G, Johnson BG, Peeva E, Vincent MS, Clerin VM. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-07261271 in healthy participants. Br J Clin Pharmacol. 2026 Jun 3. doi: 10.1002/bcp.70602. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-07261271	Unknown	300 mg	Intravenous

Indications

No indication recorded.